{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:11:25Z","timestamp":1779927085919,"version":"3.53.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81573472 and 81770004"],"award-info":[{"award-number":["81573472 and 81770004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"13th Five-Year Plan of National Major Science and Technology Projects of China","award":["2018ZX09201-013"],"award-info":[{"award-number":["2018ZX09201-013"]}]},{"name":"Clinical Research Support Funding of PLA General Hospital","award":["2016FC-TSYS-2043"],"award-info":[{"award-number":["2016FC-TSYS-2043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The clinical significance of using vancomycin loading dose remains controversial. A systematic review and meta-analysis were performed to assess the clinical efficacy and safety of vancomycin loading dose in the treatment of infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The Pubmed, Embase, Web of Science, and Cochrane Library databases were searched from their inception up to 5 May 2019. Randomized controlled trials (RCTs) and other observational studies were included if they provided clinical outcomes or trough concentrations of vancomycin loading dose (20\u201330\u200amg\/kg) and conventional-dose (10\u201320\u200amg\/kg) in the treatment of infections. Achievement of therapeutic concentration (serum trough concentrations of vancomycin reached 15\u201320\u200amg\/L before the second dose), clinical response (clinical improvement or culture-negative), nephrotoxicity (serum creatinine increase \u22650.5\u200amg\/dL or \u226550% increasing from the baseline), other adverse events (including pruritus, flushing, rash, and\/or red man syndrome), and mortality were analyzed. Heterogeneity was identified using the Cochrane <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup> statistic, and <jats:italic toggle=\"yes\">P<\/jats:italic>-value &lt;.10 or <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>-values &gt;50% indicated significant heterogeneity. Pooled estimates of the intervention effects were determined by the odds ratios (ORs) and 95% confidence intervals (CIs) in Review Manager program, version 5.3.5.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Two RCTs and 7 cohort studies including 2816 infected patients were selected for the analysis, in which serum trough concentrations of vancomycin following the use of vancomycin loading dose or other outcomes were available. Loading dose group had a significantly higher compliance rate of serum trough concentration of 15 to 20\u200amg\/L (OR\u200a=\u200a3.06; 95% CI\u200a=\u200a1.15\u20138.15; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03) and significantly lower incidence of nephrotoxicity (OR\u200a=\u200a0.59, 95% CI\u200a=\u200a0.40\u20130.87; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.008; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a29%) compared with control group. No significant difference was noted between loading dose group and control group in terms of other adverse events and clinical response (OR\u200a=\u200a1.98, 95% CI\u200a=\u200a0.80\u20134.93; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.14; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a0%). The use of vancomycin loading doses in patients can indeed increase the achievement of therapeutic concentration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Vancomycin loading dose increases the achievement of therapeutic concentration without bringing extra risk of nephrotoxicity. However, well-designed large-scale RCTs remain needed to validate the clinical efficacy of vancomycin loading dose and to further evaluate other adverse reactions and mortality.<\/jats:p>\n            <jats:p>PROSPERO registration number CRD42018093927<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017639","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T19:22:49Z","timestamp":1571858569000},"page":"e17639","source":"Crossref","is-referenced-by-count":28,"title":["The clinical efficacy and safety of vancomycin loading dose"],"prefix":"10.1097","volume":"98","author":[{"given":"Hekun","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10]]},"reference":[{"issue":"(Suppl 1)","key":"R1-20240516","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R2-20240516","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R3-20240516","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.36.8.1766","article-title":"Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response","volume":"36","author":"Ackerman","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20240516","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R5-20240516","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R6-20240516","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J Infect Chemother"},{"key":"R7-20240516","first-page":"975","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011"},{"key":"R8-20240516","first-page":"1654","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Ne","year":"2013"},{"key":"R9-20240516","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.clinthera.2013.05.008","article-title":"A stewardship program's retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","author":"Gawronski","year":"2013","journal-title":"Clin Ther"},{"key":"R10-20240516","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R12-20240516","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R13-20240516","first-page":"281","article-title":"Guide to clinical preventive services. Report of the US Preventive Services Task Force","volume":"91","author":"Allen","year":"1991","journal-title":"J Am Osteopath Assoc"},{"key":"R14-20240516","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/INF.0b013e3182a26774","article-title":"A randomized controlled trial of a vancomycin loading dose in children","volume":"32","author":"Demirjian","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20240516","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1060028014556813","article-title":"A randomized trial of loading vancomycin in the emergency department","volume":"49","author":"Rosini","year":"2015","journal-title":"Ann Pharmacother"},{"key":"R16-20240516","doi-asserted-by":"crossref","first-page":"616","DOI":"10.7196\/SAMJ.5343","article-title":"The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients","volume":"102","author":"Cheong","year":"2012","journal-title":"S Afr Med J"},{"key":"R17-20240516","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1445-5994.2011.02459.x","article-title":"Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels","volume":"42","author":"Truong","year":"2012","journal-title":"Intern Med J"},{"key":"R18-20240516","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jcrc.2013.01.004","article-title":"Evaluation of a vancomycin dosing nomogram based on the modification of diet in renal disease equation in intensive care unit patients","volume":"28","author":"Golenia","year":"2013","journal-title":"J Crit Care"},{"key":"R19-20240516","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/acem.12934","article-title":"High single-dose vancomycin loading is not associated with increased nephrotoxicity in emergency department sepsis patients","volume":"23","author":"Rosini","year":"2016","journal-title":"Acad Emerg Med"},{"key":"R20-20240516","doi-asserted-by":"crossref","first-page":"e00280-17","DOI":"10.1128\/AAC.00280-17","article-title":"Pharmacokinetic assessment of vancomycin loading dose in critically Ill patients","volume":"61","author":"\u00c1lvarez","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20240516","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/1120009X.2017.1389807","article-title":"Effect of vancomycin initial dosing on time to systemic inflammatory response syndrome resolution in patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"30","author":"Wesolek","year":"2018","journal-title":"J Chemother"},{"key":"R22-20240516","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jemermed.2019.03.020","article-title":"An evaluation of the incidence of nephrotoxicity after a loading dose of vancomycin in patients with severe renal impairment","volume":"56","author":"Marvin","year":"2019","journal-title":"J Emerg Med"},{"key":"R24-20240516","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jac\/27.6.875","article-title":"Necessity of a loading dose when using vancomycin in critical-ill patients","volume":"27","author":"Soto","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"R25-20240516","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2005.11.009","article-title":"Loading dose of vancomycin in critically ill patients: 15\u200amg\/kg is a better choice than 500\u200amg","volume":"27","author":"Mohammedi","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"R26-20240516","first-page":"436","article-title":"Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study","volume":"65","author":"El Nekidy","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20240516","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/47.2.246","article-title":"Necessity of a loading dose when using vancomycin in critically ill patients","volume":"47","author":"Wang","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"R28-20240516","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2710.2004.00572.x","article-title":"High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion","volume":"29","author":"Vuagnat","year":"2004","journal-title":"J Clin Pharm Therap"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T22:08:43Z","timestamp":1715897323000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017639"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":26,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017639","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}